It’s so small, not even the size of a dime! But a teeny, tiny device is helping the hearts of some of the most vulnerable ...
Add Yahoo as a preferred source to see more of our stories on Google. Abbott laboratories in Sunnyvale, Calif., on Aug. 24, 2019. Abbott said last week that it has received clearance to sell a device ...
First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heart New delivery system enables precise ...
Results reinforce that Amplatzer Piccolo™ Occluder is safe and effective for closing an opening in the heart known as a "patent ductus arteriosus" (PDA) in newborns Study found low adverse event rates ...
The US Food and Drug Administration (FDA) has approved the Amplatzer Piccolo Occluder (Abbott), the first medical device to treat patent ductus arteriosus (PDA) in premature babies weighing as little ...
In 2019, the U.S. Food and Drug Administration approved the first PDA occlusion device for infants as small as 700 grams, leading to rapid adoption of tcPDA in premature infants. Catheter-based ...
Active treatment of hemodynamically significant patent ductus arteriosus (PDA) in preterm infants within the first 2 weeks of life was associated with worse outcomes than expectant management.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results